Literature DB >> 9491329

Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus.

B Singh1, M M Ittmann, J J Krolewski.   

Abstract

Cowden disease, a dominantly inherited syndrome characterized by a variety of proliferative lesions and predisposition to breast and thyroid cancer, has recently been linked to the polymorphic marker D10S215 on chromosome segment 10q23. Loss of heterozygosity in prostate cancer is linked to the same marker, whereas loss of heterozygosity in glioblastoma, endometrial cancer, and other malignancies also localizes to this region. Most recently, a putative tumor suppressor gene (PTEN/MMAC1) has been identified in the region between D10S215 and an adjacent, more telomeric marker (D10S541) and was found to be altered in breast cancers, prostate cancers, and glioblastomas. We examined 22 invasive breast cancers for loss of heterozygosity in the 10q23 region and found loss in 41% (9/22). There were two distinct regions of loss, including one near the D10S541 marker, with an approximately equal frequency of deletion in each. The observed pattern of deletion is consistent with the presence of a tumor suppressor gene between D10S215 and D10S541. Most of the poorly differentiated carcinomas in the case collection showed loss of heterozygosity in the region near D10S215, suggesting that this loss correlates with a poor prognosis.

Entities:  

Mesh:

Year:  1998        PMID: 9491329

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  30 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.

Authors:  Ping Li; Artour Torossian; Qing Zhang; Wen-Cai Xu; Shen Fu
Journal:  Med Oncol       Date:  2012-06-23       Impact factor: 3.064

4.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

5.  Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers.

Authors:  I De Vivo; D M Gertig; S Nagase; S E Hankinson; R O'Brien; F E Speizer; R Parsons; D J Hunter
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

6.  Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Authors:  Linda S Steelman; Patrick Navolanic; William H Chappell; Stephen L Abrams; Ellis W T Wong; Alberto M Martelli; Lucio Cocco; Franca Stivala; Massimo Libra; Ferdinando Nicoletti; Lyudmyla B Drobot; Richard A Franklin; James A McCubrey
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

7.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.

Authors:  B Kwabi-Addo; D Giri; K Schmidt; K Podsypanina; R Parsons; N Greenberg; M Ittmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

8.  The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients.

Authors:  Nikola Tanic; Zorka Milovanovic; Nasta Tanic; Radan Dzodic; Zorica Juranic; Snezana Susnjar; Vesna Plesinac-Karapandzic; Svetislav Tatic; Tatjana Dramicanin; Radoslav Davidovic; Bogomir Dimitrijevic
Journal:  Cancer Biol Ther       Date:  2012-08-15       Impact factor: 4.742

9.  Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: their role in malignancy development and response to therapy.

Authors:  Zorica Milosevic; Nikola Tanic; Jasna Bankovic; Tijana Stankovic; Marko Buta; Dragana Lavrnic; Zorka Milovanovic; Gordana Pupic; Sonja Stojkovic; Vedrana Milinkovic; Yasuhiro Ito; Radan Dzodic
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

Authors:  L S Steelman; P M Navolanic; M L Sokolosky; J R Taylor; B D Lehmann; W H Chappell; S L Abrams; E W T Wong; K M Stadelman; D M Terrian; N R Leslie; A M Martelli; F Stivala; M Libra; R A Franklin; J A McCubrey
Journal:  Oncogene       Date:  2008-03-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.